Drugs / RBT-9
RBT-9
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04072861 | Mar 2019 → Jul 2020 | chronic kidney disease | Renibus Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03630029 | Sep → Nov 2018 | acute kidney injury | Renibus Therapeutics, Inc. | Withdrawn | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04364763 | Aug 2020 → Sep 2021 | COVID-19 | Renibus Therapeutics, Inc. | Terminated | Mixed Stop: Enrollment |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT04371822 Comparator | Aug → Oct 2020 | COVID-19 | Kafrelsheikh University | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RBT-9 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04072861 ↗ |
| Known as | SnPP | “FeS (Iron Sucrose) SnPP (Stannous Protoporpyhrin” NCT03630029 ↗ |
| Known as | Stannous Protoporphyrin | “12 healthy volunteers will be administered a single dose of 12 mg Iron Sucrose and 9 mg of Stannous Protoporphyrin and followed for seven days.” NCT03630029 ↗1“will receive a single dose of 7 mg of Stannous Protoporphyrin and They will be exposed to sunlight two hours every day for 14 days” NCT04371822 ↗ |
| Known as | Stannous Protoporpyhrin | “FeS (Iron Sucrose) SnPP (Stannous Protoporpyhrin” NCT03630029 ↗ |
| Modality | Small molecule | — CHEMBL5095194 ↗ |
| Route | Intravenous | “administered intravenously over a 120-minute period on Day 1.” NCT04364763 ↗ |